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It is well-known that carcinogenesis and further 
tumor progression are based on cell genetic damage 
and genome instability. Structural chromosome altera-
tions play a major role in tumor progression. Among 
the huge variety of chromosome anomalies in tumor 
cells, the specific or primary karyotype alterations 
are defined which are specific for certain tumor and 
leukemia types, and without any doubt are related 
to pathogenesis of these diseases. Structural mal-
functions (translocations, deletions, inversions and 
amplifications) of oncogenes coding growth factors, 
cell receptors and other proteins, which control cell 
division and differentiation, are referred as primary 
chromosome alterations. Oncogene activation, tumor 
suppressor gene transfer, loss or damage, and also 
occurrence of structural DNA recombination due to 
translocation, which lead to forming of chimeric pro-
teins, play the significant role in the neoplastic trans-
formation and processes of tumor progression [1, 2].
Interferons (IFN) are typical representatives of so-
called “biological reaction modifiers” which are incorpo-
rated into interaction between the tumor and the orga-
nism, providing non-specific anti-tumor defenses and 
enhancing specific organism-to-tumor response [3–5].
It is known that many IFN-induced genes belong 
to tumor suppressors [6–12]. On the other hand, inte-
gration of oncogenic virus DNA or cell transformation 
could be accompanied by damage of intracellular 
components of IFN system [10, 13–15]. IFNs can be 
referred to considerably small group of endogenous 
bioregulators, which can protect cells and their ge-
nome from various lesions. First of all, IFN is a classic 
anti-virus agent that prevents the replication of onco-
genic virus and the integration of viral/proviral DNA into 
the cellular genome [16, 17]. In addition, previously it 
was demonstrated that IFN possesses apparent anti-
mutagenic activity, and these studies derived a con-
cept that “IFN is a cell genome guardian” [4, 18, 19]. 
However, those studies were not properly conducted, 
and the mechanisms of mentioned IFN effects and 
their role in carcinogenesis had not been studied yet.
Two main aspects of the problem of IFN participa-
tion in cell genetic consistence control can be derived. 
One of them, as have been mentioned previously, is 
related to the IFN’s ability of direct participation in the 
control of cell genetic consistence. The other aspect 
is related to the genome stability asserted by IFN on a 
cell population level. That aspect is also insufficiently 
studied, while it is clearly demonstrated phenomenon 
in the clinical research of efficacy of IFN therapy in 
chronic myeloid leukemia (CML) patients.
It is shown in multiple studies that IFN therapy 
application results in complete hematologic as well 
as cytogenetic remission in about 70–80% of CML 
patients. An apparent alteration in cell population 
structure is detected in the blood of 30–40% of such 
patients [20]. This made possible to search for a new 
CML treatment tactics, switching from hematologic 
onset control to tumor clone suppression. That op-
portunity is confirmed by diminishing the levels of 
Ph+ cells and restoration of normal hemopoiesis if the 
IFN is used. While therapeutic efficacy of IFN in CML 
treatment is proven [20, 21], the precise mechanism of 
IFN-mediated tumor growth suppression remains un-
known. So far, there was only one in vitro study, which 
demonstrated the unique ability of IFN to selectively 
inhibit the reproduction of Ph+ stem leukemic cells. 
IFN did not prevent the proliferation of normal bone 
marrow hematopoietic precursor cells. Probably, the 
mechanism of cytogenetic remission in CML patients 
during IFN therapy is in precise genetic selection of cell 
population [22]. Unfortunately, besides the wide use 
of IFN for the treatment of patients with solid tumors, 
these IFN-mediated effects have not been studied 
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in the cells of solid tumors, in particular in the cells 
of non-small lung cancer.
At the time, if cells that occur spontaneously during 
neoplastic transformation loose sensitivity to various 
cytokines, this may lead to the accumulation of more 
aggressive tumor clones. For example, a deletion of chro-
mosome I short arm is often found in solid tumors, and 
its presence is associated with tumor progression [23].
In current study we have performed a comparative 
analysis of A-549 cells and its subline A-549IFN that was 
modified by long-term action of IFN in vitro, to evaluate 
the ability of IFN to influence on karyotype characteristics 
of tumor cells and on the structure of cell population.
MATERIALS AND METHODS
Non-small cell lung cancer cell line (NSCLC) 
A-549 obtained from the Collection of Cell Lines of IEPOR 
NASU (Kiev, Ukraine) was cultured in complete RPMI 
1640 medium supplemented with 4 mM L-glutamine, 
10% fetal bovine serum, 40 μg/ml of gentamycine and 
50 g/ml of amphotericin B (Sigma, USA) in humidified 
atmosphere containing 5% CO2, 37 °C. The concentra-
tion of IFN in A-549IFN cells media is 10 000 U/ml. The 
medium was replaced each two days, and cell passages 
were performed each four days with trypsin-versen 
solution. To study the long-term effect of IFN, the cells 
were cultivated for 1 year in the presence of recombinant 
IFN-alpha-2b (BioPharma, Ukraine) at increasing con-
centrations (from 100 to 10 000 U/ml) of INF. As a result, 
A-549 subline was obtained (A-549IFN) [7].
For a morphologic investigation, cytospin speci-
mens were dried and Papenheim-stained. The levels 
of dividing cells, binuclear cells, cells containing micro-
nuclei and apoptotic cells occurrence were calculated 
per 1000 cells and figured in per miles (‰). Chromo-
some specimens were prepared as it was described 
earlier [24].
Stained specimens were analyzed using Axiostar 
Plus microscope (Carl Zeiss, Germany) at x400–
1000 magnification. Specimens of live and stained 
cells were photographed using Canon PowerShot 
G5 digital photo camera (Canon, Great Britain).
The statistical significance of the differences be-
tween mean values was assessed by the Student’s 
t-test.
RESULTS AND DISCUSSION
An amount of chromosomes in the metaphase 
plates of A-549 cell culture varied from 15 to 63. Modal 
class in these cells comprised of 54–59 chromosomes; 
the majority of cells (28%) contained 56 chromosomes 
(Fig. 1). The characteristic feature of A-549 cell line is 
a giant submetacentric chromosome, which has been 
detected in more than 60% of observed metaphases 
(Fig. 2). Differential staining showed the marker chro-
mosome as a result of translocation of a short arm 
chromosome 2 fragment onto a short arm of chromo-
some 1 (Fig. 3). This observation is consistent with the 
results of other studies of A-549 cell populations [25]. 
Nestor A.L. et al. [25] described among the marker 
chromosomes the most frequent translocations der (3) 
t (3, 20), der (6) t (6; 1), der (19) t (15; 19), + der (19) 
t (15; 19), del (2), der (11) t (8; 11). In current study we 
observed the presence of rearranged chromosomes 
previously described among the marker chromosomes 
of this line, as der (6) t (6; 1), der (11) t (8; 11), der (2) 
t (2, 1) in the metaphase plate of A-549 cells prior IFN 
treatment. Relatively low frequency (6% — 25%) of re-
built chromosome der (6) t (6; 1) in the initial population 
cells A-549 should be noted.
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Fig. 1. Characteristics of modal class of chromosomes 
of A-549 cells
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Fig. 2. Typical metaphase plates of A-549 cells with giant sub-
metacentric chromosomes (arrows)
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Fig. 3. Differential staining of marker chromosome with trans-
location t (1; 2) in the cell clones dominated in the parental cell 
line A-549
Studies conducted using the method of fluores-
cence in situ hybridisation of DNA probes to different 
chromosomes showed a high initial heterogeneity of 
A-549 cell population on the marker chromosomes 
[26]. It is estimated that about 25% of chromosomes 
of this line are involved in various chromosomal re-
arrangements. It was shown previously that such 
rearrangements results in marked increase of chro-
mosome 1 copies compared to other autosomes 
(5.8 ± 1.4 copies of chromosome 1 in the karyotype) 
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[26]. The high degree of heterogeneity of rearranged 
marker chromosomes in A-549 cell population makes 
it difficult to allocate some marker chromosomes or 
chromosome combinations among them [25, 26]. 
At the same time, translocation of the long arm of 
chromosome 1, which is most easily identified by dif-
ferential staining, allows to track the impact of various 
external factors on the structure of the cell population.
The experiments performed earlier described the 
data of incorporation of chromosome 1 in intra- and 
interchromosomal recombination in the tumor cells 
of various origins. Thus, for example, patients with 
germinogenic tumors often have normal karyotype, 
but an aberration in chromosome 1 occurs frequently, 
for example, the short arm of chromosome 1 can be 
doubled or lost [27]. The most frequent chromosomal 
aberration in neuroblastoma patients is a deletion of 
chromosome 1 short arm — del (1p) [23].
Translocation 1; 2 (q25; p23) is detected in some 
anaplastic giant cell lymphoma patients [28]. Au-
thors suggest that the Tmp3 gene on the chromo-
some 1 (q25) and anaplastic lymphoma kinase (ALK) 
gene on 2p23 arm are incorporated in this transloca-
tion [29], and the translocation is accompanied by the 
expression 104 kDa chimera protein TMP3-ALK [28].
The A-549IFN cell line was derived from original 
A-549 cell line by long-term cultivation in the pres-
ence of IFN. Previously we have shown that prolonged 
treatment of A-549 cells with IFN leads to significant 
changes in their phenotypic properties, many of which 
persist for a long time (up to two months) even in the 
absence of IFN [30]. Therefore, we proposed that this 
could not be the result of constant induction of genes 
expression by IFN: new features of A-549IFN cells could 
be explaned by stable genetic and epigenetic changes 
due to IFN-induced selection of cell population.
Cytogenetic analysis of IFN-modified cells 
(A-549IFN), held in the dynamics at different stages of 
new subline formation, showed profound changes in the 
clonal composition of these cells. It was shown that in 
new cell population modal class of chromosomes varies: 
an amount of chromosomes in the metaphase plates of 
A-549IFN cell culture varied mostly from 48 to 66, modal 
class in these cells included 58–62 chromosomes 
(Fig. 4). A majority of these cells contained 62 chro-
mosomes. In the cells dominating in the population 
changes occured with a specific marker chromosomes: 
the number of metaphases with chromosomal rear-
rangement der (6) t (6, 1) greatly increased (from 6% 
to 80%, p < 0.001), and cells with marker der (2) t (2, 1) 
almost disappeared from population (see Fig. 3; Fig. 5). 
Thus, these data demonstrate the process of clonal se-
lection in A-549 cells under the long-term action of IFN, 
like that of described earlier for CML cells [22]. A typical 
feature of the A-549IFN subline is a significant decrease 
in frequency of cell division and pseudometaphases 
formation (p < 0.001), and small increase of number 
of cells with micronuclei (Table). The higher sensitivity 
of these cells to apoptosis demonstrated in previous 
studies [30] could explain current observations. It was 
found that cultivation of IFN-modified A-549IFN cells 
in the absence of IFN for 45 days was accompanied by 
further cytogenetic and phenotypic unification of the 
population — the dominance of clones with markers 
der (6) t (6, 1), modal number of 54–59 chromosomes 
in 80% of cells. Observed characteristics of chromo-
some modal class indicate the decrease of aneuploidy 
in the new cell population of A-549IFN line. This is in 
line with previous data on the decrease of indices of 
malignant phenotype of these cells compared with 
parental A-549 line [30].
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Fig. 4. Characteristic of modal class chromosomes in A-549IFN 
cells
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Fig. 5. Differential staining of marker chromosome with trans-
location t (6, 1) in the cell clones dominated in A-549IFN subline
Table. The frequency of occurrence of cell division, pseudometaphases and 
cells with micronuclei and apoptotic cells in A-549 and A-549IFN cell line
Cell line
Number 
of studied 
cells
Frequency of occurrence (‰)
Pseudometa-
phases Mitosis Micronuclei Apoptosis
A-549 8000 5.6 ± 1.0 12.2 ± 1.9 2.6 ± 0.8 4.5 ± 1.5
A-549IFN 7000 1.4 ± 0.9* 3.6 ± 0.8* 5.7 ± 1.4 1.9 ± 0.5
*p < 0.001.
Thus, obtained results directly demonstrate that in 
the presence of IFN clonal selection take place in the 
original cell population and gives rise to a new sub-
line, which differs from the original line by a number 
of biological and phenotypic parameters describe 
earlier [30]. Karyological changes that we identified 
in A-549IFN cells, as well as continuous changes in 
the expression level of several protein markers indi-
cate the presence of both the adaptive and selective 
mechanism in the reaction of cells in response to IFN 
[31, 32]. The cell system, which was developed, could 
be perspective to reveal the role of adaptive and se-
lective mechanisms in the emergence of a new, less 
malignant cell clones under long-term action of IFN.
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